Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Steven Seedhouse
CANT
Steven Seedhouse
Wall Street Analyst
★☆☆☆☆
#2424
on 13Foresight · ranked by our own returns
37%
Success Rate
+6.4%
Average Return
14 of 38 calls profitable · -15.5% vs benchmark
📈 Across the calls we could measure, roughly 37% of Steven Seedhouse's ratings turned a profit when each position was held for 2 year — averaging +6.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

70 Buy 7 Hold 0 Sell
Steven's Stock Coverage 42 ratings · 2026-06-19
Company Date Position Consensus Price Target 2-Yr Return
SE:VICO
Vicore Pharma Holding AB
Jun 08, 2026 BUY Strong Buy
+208.7% avg upside
2 analysts
$33.00
186.91% Upside
·
ALGS
Aligos Therapeutics
May 28, 2026 BUY Strong Buy
+772.5% avg upside
11 analysts
$20.00
278.75% Upside
·
BLTE
Belite Bio, Inc. ADR
May 20, 2026 BUY Strong Buy
+25.0% avg upside
10 analysts
$266.00
81.97% Upside
-3.6%
WVE
Wave Life Sciences
May 18, 2026 BUY Strong Buy
+261.8% avg upside
28 analysts
$13.00
110.96% Upside
-3.8%
IRD
Opus Genetics
May 13, 2026 BUY Strong Buy
+154.9% avg upside
23 analysts
$15.00
268.62% Upside
-22.2%
HROW
Harrow Health
May 12, 2026 BUY Strong Buy
+25.5% avg upside
12 analysts
$88.00
105.24% Upside
+44.5%
PHVS
Pharvaris
May 12, 2026 BUY Strong Buy
+37.3% avg upside
14 analysts
$46.00
40.24% Upside
+6.9%
IFRX
InflaRx
May 08, 2026 BUY Buy
+390.3% avg upside
11 analysts
$4.00
121.01% Upside
-7.8%
CAMP
CAMP4 Therapeutics Corporation
May 08, 2026 BUY Strong Buy
+131.4% avg upside
9 analysts
$7.00
69.58% Upside
-0.2%
ABCL
AbCellera Biologics
May 05, 2026 BUY Strong Buy
+139.4% avg upside
15 analysts
$7.00
26.51% Upside
-5.4%
VKTX
Viking Therapeutics
Apr 30, 2026 BUY Strong Buy
+141.1% avg upside
30 analysts
$100.00
229.13% Upside
-4.9%
PRQR
ProQR
Apr 14, 2026 BUY Strong Buy
+516.3% avg upside
18 analysts
$8.00
323.27% Upside
-26.9%
EQ
Equillium
Apr 07, 2026 BUY Strong Buy
+183.0% avg upside
14 analysts
$10.00
227.90% Upside
+44.3%
INVA
Innoviva
Apr 07, 2026 BUY Buy
+27.2% avg upside
12 analysts
$32.00
42.36% Upside
-2.8%
TVRD
Tvardi Therapeutics
Apr 01, 2026 HOLD Buy
+588.1% avg upside
23 analysts
+10.0%
SRZN
Surrozen
Mar 23, 2026 BUY Buy
+49.6% avg upside
7 analysts
$40.00
71.98% Upside
-4.8%
JP:4593
Healios KK
Mar 17, 2026 BUY Strong Buy
+189.5% avg upside
3 analysts
$1130.00
338.07% Upside
·
KRRO
Korro Bio
Mar 12, 2026 BUY Strong Buy
+108.3% avg upside
19 analysts
$22.00
69.44% Upside
-3.9%
XNCR
Xencor
Feb 25, 2026 BUY Strong Buy
+159.5% avg upside
27 analysts
$43.00
240.13% Upside
-5.9%
NAMS
NewAmsterdam Pharma Company
Feb 19, 2026 BUY Strong Buy
+56.4% avg upside
18 analysts
$49.00
64.26% Upside
-13.9%
BCRX
BioCryst
Jan 12, 2026 BUY Strong Buy
+103.2% avg upside
24 analysts
$26.00
189.25% Upside
+18.9%
ALNY
Alnylam Pharma
Apr 28, 2025 HOLD Strong Buy
+23.4% avg upside
51 analysts
$250.00
10.10% Downside
+11.0%
QTTB
Q32 Bio
Dec 11, 2024 BUY Buy
+345.2% avg upside
24 analysts
$22.00
84.78% Upside
-7.6%
GILD
Gilead Sciences
Nov 08, 2024 BUY Strong Buy
-4.8% avg upside
66 analysts
$103.00
16.75% Downside
+34.5%
EDIT
Editas Medicine
Nov 04, 2024 HOLD Buy
+420.3% avg upside
33 analysts
-8.2%
ZURA
Zura Bio
May 10, 2024 BUY Strong Buy
+289.3% avg upside
12 analysts
$17.00
353.32% Upside
+2.4%
DNTH
Dianthus Therapeutics
Apr 18, 2024 BUY Strong Buy
+8.9% avg upside
29 analysts
$51.00
38.27% Downside
+294.7%
DYN
Dyne Therapeutics
Jan 03, 2024 BUY Strong Buy
+93.5% avg upside
29 analysts
$56.00
182.75% Upside
+25.2%
MIRM
Mirum Pharmaceuticals
Oct 18, 2023 BUY Strong Buy
+7.5% avg upside
21 analysts
$77.00
28.05% Downside
+163.0%
CYPH
Cypherpunk Technologies
Jun 23, 2023 BUY Buy
+1087.0% avg upside
9 analysts
$17.00
2199.84% Upside
·
NTLA
Intellia Therapeutics
May 05, 2023 BUY Buy
+153.7% avg upside
37 analysts
$78.00
397.79% Upside
-80.8%
RCKT
Rocket Pharmaceuticals
May 05, 2023 BUY Buy
+395.9% avg upside
29 analysts
$35.00
944.74% Upside
-62.6%
KYMR
Kymera Therapeutics
May 04, 2023 BUY Strong Buy
+9.0% avg upside
36 analysts
$38.00
57.94% Downside
+34.4%
MDGL
Madrigal Pharmaceuticals
Dec 19, 2022 HOLD Strong Buy
-5.8% avg upside
31 analysts
+24.9%
GOSS
Gossamer Bio
Dec 07, 2022 BUY Buy
+4381.2% avg upside
17 analysts
$5.00
2876.24% Upside
-65.3%
ANAB
AnaptysBio
Nov 09, 2022 BUY Strong Buy
+26.1% avg upside
26 analysts
$38.00
33.83% Downside
-27.2%
ARCT
Arcturus Therapeutics
Aug 10, 2022 SELL Buy
+291.8% avg upside
35 analysts
-3.4%
GLMD
Galmed Pharmaceuticals
May 18, 2022 HOLD Buy
+4115.6% avg upside
13 analysts
-95.0%
NEXI
NexImmune
Feb 22, 2022 BUY Buy
+7499900.0% avg upside
4 analysts
$13.00
12999900.07% Upside
·
GYRE
Gyre Therapeutics
Aug 06, 2021 BUY Strong Buy
+212.0% avg upside
15 analysts
$18.00
188.08% Upside
-53.6%
BIIB
Biogen
Jul 22, 2021 HOLD Strong Buy
+25.1% avg upside
51 analysts
-15.2%
CRSP
Crispr Therapeutics AG
Jun 13, 2021 SELL Buy
+39.7% avg upside
41 analysts
+52.8%
🔒 37 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Steven Seedhouse — Frequently Asked Questions
How accurate are Steven Seedhouse's stock ratings?
Based on the calls 13Foresight could measure, about 32% of Steven's ratings were profitable over a one-year hold, with an average return of -5.7% per rating, or -16.0% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Steven ranked on 13Foresight?
Steven Seedhouse is currently ranked #2424 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Steven cover?
Steven most recently has ratings on SE:VICO, ALGS, BLTE, WVE, IRD, HROW, PHVS, IFRX, CAMP, ABCL, VKTX, PRQR and 30 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.